Gataparsen Explained

Gataparsen (development code LY2181308) is an antisense oligonucleotide that complementarily binds to survivin mRNA and inhibits its expression in tumor tissue.^[1]

It being investigated for a number of different cancers.^[2]

It is targeted at survivin which prevents cells dying.^[3]

Clinical trials

It has completed a phase II trial for acute myeloid leukemia.^[4]

A phase II trial for non-small cell lung cancer has started.^[5]

A phase II trial for hormone-refractory prostate cancer will run until early 2012.^[6]

Notes and References

1. Tanioka M, Nokihara H, Yamamoto N, Yamada Y, Yamada K, Goto Y, Fujimoto T, Sekiguchi R, Uenaka K, Callies S, Tamura T . 6 . Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors . Cancer Chemotherapy and Pharmacology . 68 . 2 . 505–11 . August 2011 . 21079959 . 10.1007/s00280-010-1506-7 .
2. Web site: Search of: LY2181308. ClinicalTrials.gov.
3. Web site: 2019-08-31 . 2009-10-10 . https://web.archive.org/web/20091010210012/http://www.isispharm.com/Pipeline/Therapeutic-Areas/Cancer.htm . dead . Cancer . Isis Pharmaceuticals.
4. Web site: A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia. ClinicalTrials.gov.
5. Web site: Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer. ClinicalTrials.gov.
6. Web site: A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer. ClinicalTrials.gov.